Vol 89, No 1 (2018)
Research paper
Published online: 2018-01-31
Does IGF-1 play a role in the biology of ovarian cancer?
Abstract
Objectives: The aim of the study was to investigate serum concentrations of the insulin-like growth factor-1 in women with ovarian cancer and healthy controls, and to compare free IGF-1 levels with selected clinical and pathological parameters. Correlation analysis was used to measure the following: IGF-1 concentration and Ca125; IGF-1 level and the height of the OC patients.
Material and methods: The study included 70 patients with OC and 50 healthy controls. Serum concentrations of free IGF-1 were measured in all subjects. Routine diagnostic tests (CBC and USG and Ca125) were performed.
Results: Significantly higher serum concentrations of free IGF-1 were found in the study group as compared to controls. No statistically significant relationships between IGF-1 serum concentrations and tumor differentiation, histological type, and disease stage were detected. No statistically significant correlations between IGF-1 and Ca125 level or between IGF-1 and growth of OC patients were found.
Conclusions: Serum IGF-1 participates in the etiopathogenesis of ovarian cancer in menstruating women, while local synthesis of this factor and other components of the autocrine loop of the IGF-1 system play a greater role in their postmenopausal peers.
Keywords: ovarian cancerinsulin-like growth factor–1carcinogenesis
References
- Majchrzak-Baczmańska D, Malinowski A. Does IGF-1 play a role in the biology of endometrial cancer? Ginekol Pol. 2016; 87(8): 598–604.
- Cao Z, Liu LZ, Dixon DA, et al. Insulin-like growth factor-I induces cyclooxygenase-2 expression via PI3K, MAPK and PKC signaling pathways in human ovarian cancer cells. Cell Signal. 2007; 19(7): 1542–1553.
- Whitley BR, Beaulieu LM, Carter JC, et al. Phosphatidylinositol 3-kinase/Akt regulates the balance between plasminogen activator inhibitor-1 and urokinase to promote migration of SKOV-3 ovarian cancer cells. Gynecol Oncol. 2007; 104(2): 470–479.
- Kuhn W, Schmalfeldt B, Reuning U, et al. Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc. Br J Cancer. 1999; 79(11-12): 1746–1751.
- Shen MR, Lin AC, Hsu YM, et al. Insulin-like growth factor 1 stimulates KCl cotransport, which is necessary for invasion and proliferation of cervical cancer and ovarian cancer cells. J Biol Chem. 2004; 279(38): 40017–40025.
- Brokaw J, Katsaros D, Wiley A, et al. IGF-I in epithelial ovarian cancer and its role in disease progression. Growth Factors. 2007; 25(5): 346–354.
- Spentzos D, Cannistra SA, Grall F, et al. IGF axis gene expression patterns are prognostic of survival in epithelial ovarian cancer. Endocr Relat Cancer. 2007; 14(3): 781–790.
- Karasik A, Menczer J, Pariente C, et al. Insulin-like growth factor-I (IGF-I) and IGF-binding protein-2 are increased in cyst fluids of epithelial ovarian cancer. J Clin Endocrinol Metab. 1994; 78(2): 271–276.
- Yee D, Morales FR, Hamilton TC, et al. Expression of insulin-like growth factor I, its binding proteins, and its receptor in ovarian cancer. Cancer Res. 1991; 51(19): 5107–5112.
- Peeters PHM, Lukanova A, Allen N, et al. Circulating levels of insulin-like growth factor-I and risk of ovarian cancer. Int J Cancer. 2002; 101(6): 549–554.
- Peeters PHM, Lukanova A, Allen N, et al. Serum IGF-I, its major binding protein (IGFBP-3) and epithelial ovarian cancer risk: the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer. 2007; 14(1): 81–90.
- Tas F, Karabulut S, Serilmez M, et al. Clinical significance of serum insulin-like growth factor-1 (IGF-1) and insulinlike growth factor binding protein-3 (IGFBP-3) in patients with epithelial ovarian cancer. Tumour Biol. 2014; 35(4): 3125–3132.
- Fletcher O, Gibson L, Johnson N, et al. Polymorphisms and circulating levels in the insulin-like growth factor system and risk of breast cancer: a systematic review. Cancer Epidemiol Biomarkers Prev. 2005; 14(1): 2–19.
- Hankinson SE, Willett WC, Colditz GA, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet. 1998; 351(9113): 1393–1396.
- Juul A. Serum levels of insulin-like growth factor I and its binding proteins in health and disease. Growth Horm IGF Res. 2003; 13(4): 113–170.
- Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and body size: individual participant meta-analysis including 25,157 women with ovarian cancer from 47 epidemiological studies. PLoS Med. 2012; 9(4): e1001200.
- Gunnell D, Oliver SE, Donovan JL, et al. Do height-related variations in insulin-like growth factors underlie the associations of stature with adult chronic disease? J Clin Endocrinol Metab. 2004; 89(1): 213–218.
- Lukanova A, Toniolo P, Lundin E, et al. Body mass index in relation to ovarian cancer: a multi-centre nested case-control study. Int J Cancer. 2002; 99(4): 603–608.
- Lukanova A, Toniolo P, Akhmedkhanov A, et al. A cross-sectional study of IGF-I determinants in women. Eur J Cancer Prev. 2001; 10(5): 443–452.
- Ovesen P, Vahl N, Fisker S, et al. Increased pulsatile, but not basal, growth hormone secretion rates and plasma insulin-like growth factor I levels during the periovulatory interval in normal women. J Clin Endocrinol Metab. 1998; 83(5): 1662–1667.
- Gleeson HK, Shalet SM. GH responsiveness varies during the menstrual cycle. Eur J Endocrinol. 2005; 153(6): 775–779.
- Thierry van Dessel HJ, Chandrasekher Y, Yap OW, et al. Serum and follicular fluid levels of insulin-like growth factor I (IGF-I), IGF-II, and IGF-binding protein-1 and -3 during the normal menstrual cycle. J Clin Endocrinol Metab. 1996; 81(3): 1224–1231.
- Juul A, Scheike T, Pedersen AT, et al. Changes in serum concentrations of growth hormone, insulin, insulin-like growth factor and insulin-like growth factor-binding proteins 1 and 3 and urinary growth hormone excretion during the menstrual cycle. Hum Reprod. 1997; 12(10): 2123–2128.
- Guidoux S, Garnier PE, Schimpff RM. Effect of the variations of female sex hormones during the menstrual cycle upon serum somatomedin and growth-promoting activity. Horm Res. 1986; 23(1): 31–37.
- Flyvbjerg A, Mogensen O, Mogensen B, et al. Elevated serum insulin-like growth factor-binding protein 2 (IGFBP-2) and decreased IGFBP-3 in epithelial ovarian cancer: correlation with cancer antigen 125 and tumor-associated trypsin inhibitor. J Clin Endocrinol Metab. 1997; 82(7): 2308–2313.
- Waksmański B, Dudkiewicz J, Kowalski T. Changes in insulin-like growth factor I, 17-b-estradiol, and progesterone in postmenopausal women with benign and malignant ovarian tumours. Med Sci Monit. 2001; 7(5): 919–923.
- Dal Maso L, Augustin LSA, Franceschi S, et al. Association between components of the insulin-like growth factor system and epithelial ovarian cancer risk. Oncology. 2004; 67(3-4): 225–230.
- Baron-Hay S, Boyle F, Ferrier A, et al. Elevated serum insulin-like growth factor binding protein-2 as a prognostic marker in patients with ovarian cancer. Clin Cancer Res. 2004; 10(5): 1796–1806.
- Serin IS, Tanriverdi F, Yilmaz MO, et al. Serum insulin-like growth factor (IGF)-I, IGF binding protein (IGFBP)-3, leptin concentrations and insulin resistance in benign and malignant epithelial ovarian tumors in postmenopausal women. Gynecol Endocrinol. 2008; 24(3): 117–121.
- Tworoger SS, Lee IM, Buring JE, et al. Insulin-like growth factors and ovarian cancer risk: a nested case-control study in three cohorts. Cancer Epidemiol Biomarkers Prev. 2007; 16(8): 1691–1695.
- Zhang L, Curhan GC, Forman JP. Plasma insulin-like growth factor-1 level and risk of incident hypertension in nondiabetic women. J Hypertens. 2011; 29(2): 229–235.
- van Bunderen CC, Oosterwerff MM, van Schoor NM, et al. Serum IGF1, metabolic syndrome, and incident cardiovascular disease in older people: a population-based study. Eur J Endocrinol. 2013; 168(3): 393–401.
- Sesti G, Sciacqua A, Cardellini M, et al. Plasma concentration of IGF-I is independently associated with insulin sensitivity in subjects with different degrees of glucose tolerance. Diabetes Care. 2005; 28(1): 120–125.
- Rajpathak SN, Gunter MJ, Wylie-Rosett J, et al. The role of insulin-like growth factor-I and its binding proteins in glucose homeostasis and type 2 diabetes. Diabetes Metab Res Rev. 2009; 25(1): 3–12.
- Decensi A, Bonanni B, Baglietto L, et al. A two-by-two factorial trial comparing oral with transdermal estrogen therapy and fenretinide with placebo on breast cancer biomarkers. Clin Cancer Res. 2004; 10(13): 4389–4397.
- Shah NG, Bhatavdekar JM, Doctor SS, et al. Circulating epidermal growth factor (EGF) and insulin-like growth factor-I (IGF-I) in patients with epithelial ovarian carcinoma. Neoplasma. 1994; 41(5): 241–243.
- Wang Q, Liu Li, Li H, et al. Genetic and dietary determinants of insulin-like growth factor (IGF)-1 and IGF binding protein (BP)-3 levels among Chinese women. PLoS One. 2014; 9(10): e108934.
- Conover CA, Hartmann LC, Bradley S, et al. Biological characterization of human epithelial ovarian carcinoma cells in primary culture: the insulin-like growth factor system. Exp Cell Res. 1998; 238(2): 439–449.
